Form 4: Protara Therapeutics CEO Jesse Shefferman Reports Changes in Beneficial Ownership
SEC Form 4
Protara Therapeutics CEO Jesse Shefferman reports disposition of common stock via gift.
Summary
- On August 28, 2024, Jesse Shefferman, CEO and President of Protara Therapeutics, reported changes in beneficial ownership of the company's common stock.
- Shefferman disposed of 5,263 shares and 3,300 shares of common stock through gifts.
- Following these transactions, Shefferman directly owns 935,501 shares of Protara Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities.
Stakeholder Impact
- The transaction may have a minor impact on shareholder sentiment, depending on how the market interprets the CEO's stock disposal.
Key Dates
| Date | Description |
|---|---|
| 08/28/2024 | Date of transaction (disposal of shares via gift) |
| 08/30/2024 | Date of signature on the Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.